Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of docetaxel and bexarotene.
Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R. Wildi JD, et al. Chemotherapy. 2008;54(2):125-30. doi: 10.1159/000119706. Epub 2008 Mar 7. Chemotherapy. 2008. PMID: 18332628 Clinical Trial.
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE. Fracasso PM, et al. Among authors: wildi jd. Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8. doi: 10.1007/s00280-008-0756-0. Epub 2008 Apr 15. Cancer Chemother Pharmacol. 2009. PMID: 18414864 Clinical Trial.
A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.
Fracasso PM, Goodner SA, Wildi JD, Naughton MJ, Linette GP, Govindan R, Tan BR, Blum KA, Jones GJ, Pearce TE, Levitt DJ, Clamon GH. Fracasso PM, et al. Among authors: wildi jd. Am J Clin Oncol. 2022 Jul 1;45(7):294-297. doi: 10.1097/COC.0000000000000924. Epub 2022 Jun 1. Am J Clin Oncol. 2022. PMID: 35700081 Free PMC article. Clinical Trial.
Beta-cell specific Insr deletion promotes insulin hypersecretion and improves glucose tolerance prior to global insulin resistance.
Skovsø S, Panzhinskiy E, Kolic J, Cen HH, Dionne DA, Dai XQ, Sharma RB, Elghazi L, Ellis CE, Faulkner K, Marcil SAM, Overby P, Noursadeghi N, Hutchinson D, Hu X, Li H, Modi H, Wildi JS, Botezelli JD, Noh HL, Suk S, Gablaski B, Bautista A, Kim R, Cras-Méneur C, Flibotte S, Sinha S, Luciani DS, Nislow C, Rideout EJ, Cytrynbaum EN, Kim JK, Bernal-Mizrachi E, Alonso LC, MacDonald PE, Johnson JD. Skovsø S, et al. Among authors: wildi js. Nat Commun. 2022 Feb 8;13(1):735. doi: 10.1038/s41467-022-28039-8. Nat Commun. 2022. PMID: 35136059 Free PMC article.